Clinical trials: CD
Crohn's Disease (CD)
A Pilot Study: Micro and NanoPlastics in Association With Crohn's Disease
Micro and nanoplastics (MNPs) are environmental contaminants found in food and water. Recent evidence suggests these particles may be linked to intestinal inflammation and changes in gut bacteria, which are key features of…
- Trial name
- NCT07630883
- Where
- Hong Kong
- Volunteers
- 90 people
- Sponsor
- Mak Wing Yan
Crohn Disease (CD), Ulcerative Colitis (UC)
Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context
Prospectively study the correlation between Leucine-rich α2-glycoprotein (LRG) and clinical/endoscopic/histological disease activity in patients with inflammatory bowel disease (IBD) in Europe.
- Trial name
- LEADER (NCT07621783)
- Testing
- Leucine-rich α2-glycoprotein
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Imelda GI Clinical Research Center
Crohn Disease (CD)
A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease
This is a multicentre, prospective, randomised, controlled, open-label study to assess the efficacy, safety, and cost-effectiveness of epigenome-guided treatment selection compared to usual standard-of-care (SOC) treatment…
- Trial name
- OMICROHN (NCT07363044)
- Testing
- Epigenome-Guided Treatment Arm, Investigator-Guided Treatment Arm
- Where
- 39 sites in Belgium, Italy and 3 more
- Volunteers
- 378 people
- Sponsor
- Alimentiv Inc.
Crohn Disease (CD), Ulcerative Colitis (UC)
Food Limitations In Crohn's Disease and Ulcerative coliTis
The goal of this clinical trial is to increase the knowledge on what type of diet affects inflammation and how to better convay that information in patients with inflammatory bowel disease (IBD) and decrease selective eating in…
- Conditions
- Crohn Disease (CD), Ulcerative Colitis (UC), IBD (Inflammatory Bowel Disease)
- Trial name
- FLIT (NCT07289672)
- Testing
- Diet, education
- Where
- Sweden
- Volunteers
- 140 people
- Sponsor
- Region Skane
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Crohn Disease (CD)
Eating Disorders in Patients With IBD
Inflammatory bowel diseases (IBD) may influence eating habits and lead some patients to adopt restrictive dietary behaviours to control gastrointestinal symptoms.
- Conditions
- Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Crohn Disease (CD), Ulcerative Colitis (UC), ARFID
- Trial name
- NCT07610694
- Where
- Italy
- Volunteers
- 355 people
- Sponsor
- Federico II University
Crohn Disease (CD)
Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease
Efficacy of Mirikizumab to achieve transmural healing in patients with Crohn's Disease
- Trial name
- EMINENT-CD (NCT07292012)
- Testing
- Mirikizumab - IV, Mirikizumab - SC
- Where
- 6 sites in France
- Volunteers
- 75 people
- Sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Crohn Disease (CD)
Qualitative Exploration of Key Symptoms of Stricturing Crohn's Disease: Toward the Development of a Clinical Assessment Score.
The goal of this qualitative study is to identify and better understand the symptoms of stricturing Crohn's disease in order to inform the development of more appropriate clinical evaluation scores.
- Trial name
- SYMCROHNS (NCT07441629)
- Testing
- Semi-structured interview
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Grenoble
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Crohn's Disease (CD)
Research on the Whole Process of AI Intelligent Management System for the Diagnosis and Treatment of Inflammatory Bowel Diseases
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic immune-mediated disorder requiring long-term management.
- Conditions
- Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Crohn's Disease (CD), Ulcerative Colitis (UC), Artificial Intelligence (AI)
- Trial name
- NCT07590271
- Where
- Taiwan
- Volunteers
- 4,500 people
- Sponsor
- Taichung Veterans General Hospital
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC)
VR Therapies for IBD
Through a pilot randomized controlled trial (RCT), the aim is to test the clinical impact and feasibility of a AI-enhanced Virtual Reality (VR) Cognitive Behavioral therapy (CBT) program versus distraction VR among patients with…
- Conditions
- Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn Disease (CD), Anxiety
- Trial name
- NCT07590518
- Testing
- Distraction VR, VR/AI CBT
- Where
- 2 sites in United States
- Volunteers
- 76 people
- Sponsor
- Brennan Spiegel
Inflammatory Bowel Diseases (IBD), Crohn Disease (CD)
NORDTREAT Prospective Study on Inflammatory Bowel Disease
Inflammatory bowel disease (IBD), primarily ulcerative colitis (UC) and Crohn's disease (CD), is a chronic disease entity affecting individuals of all ages, and which may severely impact the lives of the patients and their…
- Conditions
- Inflammatory Bowel Diseases (IBD), Crohn Disease (CD), Ulcerative Colitis (UC)
- Trial name
- NCT05414578
- Where
- 17 sites in Denmark, Iceland and 2 more
- Volunteers
- 366 people
- Sponsor
- University of Southern Denmark
Crohn Disease (CD)
WAter Preparation in Crohn's Disease's Imagery
The goal of this clinical trial is to compare distension quality and patient experience of water and polyethylene glycol preparation as oral contrast media in Magnetic Resonance Enterography (MRE) in patients with Crohn's…
- Trial name
- WAM (NCT06690632)
- Testing
- water preparation, polyethylene glycol preparation
- Where
- France
- Volunteers
- 194 people
- Sponsor
- University Hospital, Toulouse
Inflammatory Bowel Disease (IBD), Crohn&Amp;#39;s Disease (CD)
Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease
The goal of this retrospective study is to learn about dosing patterns in patients starting subcutaneous vedolizumab administration and patient outcomes after starting subcutaneous administration.
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn&Amp;#39;s Disease (CD), Ulcerative Colitis (UC)
- Trial name
- NCT07123350
- Testing
- Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Vanderbilt University Medical Center
Crohn's Disease (CD)
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedolizumab.
- Trial name
- NCT04779320
- Testing
- Vedolizumab IV
- Where
- 96 sites in United States, Australia and 16 more
- Volunteers
- 120 people
- Sponsor
- Takeda
Crohn Disease (CD), Ulcerative Colitis (UC)
the REMONO-CD and the REMONO-UC Studies
Infliximab was the first-in-class anti-TNF agent approved for treating patients with IBD, both for Crohn's disease (CD)1 and ulcerative colitis (UC)2.
- Trial name
- REMONO (NCT07564609)
- Where
- 18 sites in France
- Volunteers
- 420 people
- Sponsor
- University Hospital, Clermont-Ferrand
Crohn Disease (CD), IBD (Inflammatory Bowel Disease)
Combining Nutritional Therapy and Anti-TNFα Treatment in Pediatric Patients With Crohn's Disease
Children with Crohn's disease (CD), a type of Inflammatory Bowel Disease (IBD), often face serious health challenges, including poor growth, frequent hospital stays, and long-term medication use.
- Conditions
- Crohn Disease (CD), IBD (Inflammatory Bowel Disease), IBD - Inflammatory Bowel Disease
- Trial name
- DISPENSE-T (NCT07314606)
- Testing
- IFX + mCDED
- Where
- Canada
- Volunteers
- 140 people
- Sponsor
- University of British Columbia
Crohn Disease (CD)
Kinetics of Transmural Healing in Patients With Crohns Disease Treated With Risankizumab (SKYRIZI®)
Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) that can highly alter patients' quality of life and lead to bowel damage due to its transmural pattern.
- Trial name
- SKYNETICS (NCT07308067)
- Where
- 4 sites in France
- Volunteers
- 109 people
- Sponsor
- University Hospital, Clermont-Ferrand
IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome
ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects
This study is evaluating the levels of calprotectin, a protein found in stool, in healthy adults. Calprotectin is a marker of inflammation in the intestines and can help doctors tell the difference between inflammatory bowel…
- Conditions
- IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome, Crohn Disease (CD), UC - Ulcerative Colitis
- Trial name
- NCT07089420
- Testing
- ALPCO Calprotectin CLIA
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- American Laboratory Products Company
Castleman's Disease (CD), Idiopathic Multicentric Castleman's Disease
Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
The research study is being done to look at the effects of ruxolitinib in adults with idiopathic Multicentric Castleman Disease (iMCD) that has not gotten better from taking siltuximab or tocilizumab, or who cannot take those…
- Trial name
- NCT07085039
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Pennsylvania
Crohn's Disease (CD)
An Observational, Multicenter Study to Evaluate the Effectiveness of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
The goal of this single arm ,non-interventional, prospective, descriptive study is to evaluate the efficacy of guselkumab treatment in preventing endoscopic recurrence of Crohn's Disease in adult participants who have a…
- Trial name
- POST-CD (NCT07528040)
- Testing
- Guselkumab
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Shanghai 10th People's Hospital
Crohn's Disease (CD)
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankizumab works compared to ustekinumab.
- Trial name
- SEQUENCE (NCT04524611)
- Testing
- Risankizumab, Ustekinumab
- Where
- 300 sites in United States, Argentina and 29 more
- Volunteers
- 527 people
- Sponsor
- AbbVie